ALTRUBIO RAISES $63 MILLION SERIES A ROUND TO CONTINUE ITS COMPANY TRANSFORMATION
Endpoints News─After a major facelift, AltruBio says it's ready for a pivotal fight against graft-versus-host disease
Fierce Biotech─New name, new board, new focus: AltruBio relaunches with $63M series A
AltruBio’s Neihulizumab Granted Fast Track Designation by the FDA for Steroid Refractory Acute Graft Versus Host Disease
AltruBio to present at Biotech Showcase Digital 2021.
AltruBio Presented its Novel PSGL-1 Agonist Antibody Program for Immunological Diseases at FOCIS and Presented its Phase 2a Psoriatic Arthritis study results for lead molecule, Neihulizumab (AbGn-168H), at ACR.